New results from the SELECT2 trial also show benefit of the procedure in a large range of ischemic core sizes and in patients transferred from an outside hospital.
The STOP-CAD study signaled a short course of an antithrombotic regimen might lower ischemic stroke risk in some patients without significantly increasing major bleeding.
In patients presenting at thrombectomy-capable stroke centers, the benefit associated with thrombolysis before thrombectomy was time dependent, new data suggested.